Sector News

Actavis buys Durata in $675 million deal

October 7, 2014
Life sciences

Actavis, which is at the centre of much merger talk, is to acquire Durata Therapeutics and its antibiotic Dalvance in a deal worth at least $675 millionn.

Actavis has offered $23 per share in cash, plus a contingent value rights element of up to $5 per share depending on how well Dalvance (dalbavancin) does. The intravenous antibiotic was approved by the US Food and Drug Administration in May for acute bacterial skin and skin structure infections and it is also being developed for additional indications, such as hospitalised community-acquired pneumonia and paediatric osteomyelitis.    

Chief executive Brent Saunders said the acquisition of Durata “is a strong strategic fit that strengthens Actavis’ emerging infectious disease franchise and aligns with our stated goal to make smart, targeted investments”. He added that Dalvance complements the firm’s antibiotic Teflaro (ceftaroline fosamil) and a ceftazidine-avibactam combination, currently in late-stage development, which are intended for use in the in-patient setting.

Actavis has been reportedly in talks to buy Salix Pharmaceuticals and was rumoured to have had a $50 billion bid by Allergan turned down last month.

By Kevin Grogan

Source: Pharma Times

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach